StockWatch
·

Orkla India Ltd Q2 FY27 Results

ORKLAINDIAQ2 FY27 Results
Filing
Result:Good· Market: Surged#Broad based

Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue776.1617.8%19.4%
Total Income787.0716.4%19.1%
Expenditure664.5918.5%19.0%
PBT122.484.4%19.6%
Net Profit91.424.2%19.2%
OPM16.21%1.09pp0.17pp
NPM11.61%1.36pp0.00pp
EPS6.674.2%19.1%
View full financials

FMCG core-metric check (revenue +19.4% YoY, adj. PAT +19.2% YoY with flat NPM) shows healthy, broad-based growth without margin dilution, but sequential margin easing and no confirmable street consensus keep it just shy of a standout.

ORKLA INDIA · Q2 FY27 · THE VERDICT

₹776 Crore Quarter: Revenue Growth Can't Hide the Margin Wall

Orkla delivered 19.4% revenue growth, crushing its double-digit ambition. But EBITDA growth of just 12.6% reveals the real story: pricing power is hitting an elasticity ceiling, and margin compression is the constraint on earnings.

11 Nov 2026 · 6 min read
Reported PAT

₹91.4 Cr

+19.2% YoY

ex-PLI benefits (~₹5–6 Cr)

~₹85–86 Cr

+14–15% organic

EBITDA growth

+12.6%

vs revenue +19.4%

EBITDA margin

15.9%

−100 bps YoY

On the surface, a 19.4% revenue beat to its own double-digit ambition looks stellar. But the gap between revenue growth and EBITDA growth is where the real quarter lives. Orkla is passing pricing through — 20% in spices despite competitive intensity — but elasticity is catching up. Volumes grew just 2.9%, and management admits pricing power is capped at 2–3% annually in commodity categories. This quarter pricing won the battle; volumes lost the war. The immediate translation: earnings growth lags sales growth.

Where the reported PAT came from

Reported PAT of ₹91.4 Cr includes PLI benefits (estimated ₹5–6 Cr) and exceptional income items. Excluding these, underlying PAT growth is closer to 14–15% — still solid, but materially below the 19.2% headline. The earnings quality flag is real: operating leverage is broken near-term by inflation absorption and competitive pressure, not by weak operations.

Q2 FY27 PAT, ₹ Cr
034.1268.25102.3791.4Reported5.5PLI benefits85.9Organic (ex-PLI)
Reported PAT includes ~₹5–6 Cr in PLI benefits. Organic growth is lower, closer to 14–15% YoY.
Management's claims vs. what holds up

Revenue growth accelerated with volume growth of 2.9%

Delivered ₹776 Cr, +19.4% YoY with exactly 2.9% volume growth stated

Supported

EBITDA grew 12.6% to ₹124 Cr with 15.9% margin

124 Cr ÷ 776 Cr = 15.97% margin; growth rate matches stated 12.6% YoY

Supported

PAT grew 19.2% driven by operating performance and PLI benefits

Delivered ₹91.4 Cr YoY +19.2% as stated; PLI portion ~₹5–6 Cr embedded

Supported (but one-time-dependent)

Spices grew 25.1% with 20% pricing amid commodity inflation

Reported segment growth 25.1%; 48% commodity inflation and ~20% pricing confirmed in call

Supported

EBITDA margin moderated by 100 basis points YoY

Margin 15.9% vs prior-year baseline; compression magnitude aligns

Supported

What changed on this call

  • Volume inflection — Q2 reached 2.9% after Q1 challenges, showing pricing hasn't yet destroyed demand

  • Digital commerce scaling — Rest-of-India digital revenue +33.6% YoY; channel now 10% of domestic sales (up from 8.9% Q1)

  • Margin outlook unchanged — Management reiterates that inflation headwinds will persist through Q3–Q4 FY27; no near-term margin recovery signalled

  • International moderation — International growth 11.7% (GCC +22.7% but geopolitical risk noted) vs prior ambition for higher

The bull-bear ledger
  • Revenue beat (19.4% vs double-digit ambition) is material and real

  • Volume inflection (2.9%) shows pricing power has room before demand destruction

  • Digital commerce +33.6% YoY is a genuine new growth lever

  • EBITDA growth (12.6%) significantly lags revenue; margin compression is the constraint

  • Reported PAT growth (19.2%) inflated by PLI; organic closer to 14–15%

  • Pricing power capped at 2–3% annually; volume elasticity is tightening

  • Margin recovery is deferred to H2 FY27 onwards; no guarantee

Risks, ranked by how much they should concern a holder

Margin compression from inflation + pricing elasticity

Medium–High

EBITDA growth (12.6%) trailing revenue (19.4%) is the core problem. If commodity inflation persists and consumer elasticity tightens further, margin pressure will continue into FY28. This is the earnings growth ceiling for the next 12 months.

Volume elasticity in commodity categories

Medium

Management admits pricing power is 2–3% annually. Q2 volume of 2.9% is already at the elasticity wall. If market share losses accelerate from competitive response, volume growth could turn negative in H2.

Kerala restructuring execution risk

Medium

Margin uplift from restructuring is deferred to March 2027. Any delays or missed KPIs in the distribution network transition could push benefits further out, extending the margin headwind.

Competitive intensity in convenience foods

Medium

Wet batter (#2 position vs regional brands) and sweets (15 launches Q2 but crowded market) face established regional players. Mix deterioration from lower-margin convenience foods could further compress blended EBITDA margin.

Geopolitical volatility in GCC / International moderation

Low

International growth (11.7%) is below ambition. GCC volatility is noted but accounted for; diversification into digital and domestic offsets risk. Lower impact on earnings than domestic margin pressure.

How the street is positioned

Price action and technicals: Orkla is trading at ₹569, down 25% from its all-time high of ₹760. It is above its 20-day SMA (₹540) and 50-day SMA (₹557), but trading below the 200-day SMA (₹585). The RSI of 59.8 is neutral — neither overbought nor oversold. Volume trend is increasing, suggesting retail interest has not dried up despite the drawdown. The stock's 25% retreat from ATH suggests the market has already priced in concerns about margin compression and earnings quality. This is not a surprise downmove; it is a reassessment.

Ownership flows: FII ownership declined to 2.30% in Q1 FY27 from 2.42% in Q4 FY26 (down 12 basis points QoQ). This suggests institutional investors are cautiously trimming exposure, consistent with the margin pressure story. DII ownership is stable at 8.69% (vs 8.74% prior quarter), indicating domestic institutional support is holding. Promoter ownership is steady at 75%. There is no material insider selling or block activity signaling deeper concerns, but the FII trim is worth noting — it reflects institution-level skepticism about near-term earnings trajectory.

Valuation and drawdown context: The stock is currently ~13% below the 50-day SMA and ~2.7% below the 200-day SMA, putting it in a mild technical correction zone but not a capitulation sell-off. Relative to the ATH, the 25% drawdown is material but not severe by FMCG standards post-earnings. The street's message is clear: the headline revenue beat (19.4%) does not offset concern about margin compression and earnings quality. At ₹569, the stock is priced for steady execution, not margin recovery. Upside requires restructuring benefits to deliver materially in H2 FY27.

What to watch next
  • 1 · Q3 EBITDA margin trajectory

    Will the margin recovery begin to show in Q3 FY27, or will inflation headwinds persist? Management has promised benefits from Kerala restructuring (modern trade 50% complete by Q2, targeting December 2026) and Project Bolt scaling. A margin expansion of even 25–50 bps in Q3 would validate the restructuring thesis. Flat or further compression would extend the doubt.

  • 2 · Volume growth persistence and elasticity limits

    Can Orkla sustain 2–3% volume growth in Q3–Q4 without further deterioration? This is the key to earnings upside. If volumes dip below 2% or turn negative in any category, it signals pricing power is exhausted and margin pressure could persist into FY28.

  • 3 · Commodity price stabilization and spice margin recovery

    Management noted spice commodity inflation at 48% YoY but stated that crop cycle stabilization has brought prices to a stable level. If spice prices normalize further in H2 and Orkla can maintain 15–18% pricing actions (vs the 20% required in Q2), blended margin will expand. This is the single biggest lever for near-term margin recovery.

Orkla India delivered strong headline revenue growth in Q2 FY27, but the earnings story is constrained by margin compression and pricing elasticity. EBITDA growth of 12.6% trailing revenue of 19.4% is not a cyclical hiccup — it is a structural signal that pricing power is hitting consumer affordability limits in commodity categories. PAT growth of 19.2% is real but inflated by PLI benefits; organic growth is closer to 14–15%.

The company's restructuring bets — Project Bolt and Kerala network transition — are credible, and management tone on execution is confident. But margin uplift is deferred to H2 FY27 and FY28. For the next 6–9 months, Orkla is a steady-execution story, not a step-change story.

At ₹569, the stock reflects fair value for cautious holders. The 25% drawdown from ATH has priced in most of the margin concern. Upside is gated on two things: (1) evidence of margin recovery by Q3 FY27, and (2) confirmation that volume elasticity is not deteriorating further. Until then, this is a hold. The number to track from here is EBITDA margin — that will tell you whether management's restructuring thesis is working or whether margin compression is structural.

Informational and educational content only. Not investment advice.